Chinese clinical-stage biotech firm TransThera Biosciences has raked in about $100 million in a Series D round of financing to further the development of its pipeline products in the global market.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
